Diabetes care
-
Comparative Study Clinical Trial Controlled Clinical Trial
Whole-blood glucose testing at alternate sites: glucose values and hematocrit of capillary blood drawn from fingertip and forearm.
To measure hematocrit (Hct) and glucose concentration in capillary blood drawn from the fingertip and forearm of a group of 50 nonfasting subjects with diabetes. ⋯ In this cross-sectional study of 50 nonfasting subjects whose blood glucose concentration changed to various degrees during the experiment, no significant glucose difference was observed between the capillary beds of the forearm and fingertip, regardless of whether glucose was assayed with HemoCue or the Sof-Tact Blood Glucose System. On the other hand, Hb concentration and Hct were found to be significantly higher in the capillary blood of the forearm.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e.g., lisinopril/enalapril at 20 mg daily. We tested the concept that such patients might benefit from dual blockade of the renin-angiotensin system (RAS). ⋯ Dual blockade of the RAS reduces albuminuria and blood pressure in type 2 diabetic patients with DN responding insufficiently to previous antihypertensive therapy, including ACE inhibitors in recommended doses.
-
To characterize lower extremity function and dysfunction in peripheral artery disease (PAD) patients with and without diabetes. ⋯ Subjects with PAD and diabetes have poorer lower extremity function than those with PAD alone. This difference in functioning appears to be largely explained by diabetes-associated neuropathy, differences in exertional leg symptoms, and greater cardiovascular disease in patients with diabetes.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
The Captopril Prevention Project (CAPPP) evaluated the effects of an ACE inhibitor-based therapeutic regimen on cardiovascular mortality and morbidity in hypertension. One planned subanalysis of the CAPPP was to evaluate the outcome in the diabetic patient group. ⋯ Captopril is superior to a diuretic/beta-blocker antihypertensive treatment regimen in preventing cardiovascular events in hypertensive diabetic patients, especially in those with metabolic decompensation.